このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

BioCardia マネジメント

マネジメント基準チェック /44

BioCardia'sの CEO はPeter Altmanで、 Jan2002年に任命され、の在任期間は 22.42年です。の年間総報酬は$ 746.24Kで、 69.1%給与と30.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の2.1%を直接所有しており、その価値は$ 127.74K 。経営陣と取締役会の平均在任期間はそれぞれ8.3年と7.7年です。

主要情報

Peter Altman

最高経営責任者

US$746.2k

報酬総額

CEO給与比率	69.1%
CEO在任期間	22.5yrs
CEOの所有権	2.1%
経営陣の平均在職期間	8.3yrs
取締役会の平均在任期間	7.8yrs

経営陣の近況

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

May 14

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Oct 12

Recent updates

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

May 14

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Oct 12

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Aug 24

Shareholders May Not Be So Generous With BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation And Here's Why

Jun 08

Is BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth Plans?

May 20

BioCardia issued U.S. patent for Helix Biotherapeutic Delivery system

Dec 30

CEO報酬分析

BioCardia の収益と比較して、Peter Altman の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$746k	US$516k	-US$12m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$13m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	US$902k	US$531k	-US$12m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$1m	US$488k	-US$13m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$13m
Mar 31 2021	n/a	n/a	-US$13m
Dec 31 2020	US$883k	US$380k	-US$15m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$747k	US$363k	-US$15m
Sep 30 2019	n/a	n/a	-US$15m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$1m	US$360k	-US$14m
Sep 30 2018	n/a	n/a	-US$14m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$13m
Dec 31 2017	US$372k	US$310k	-US$12m

報酬と市場: Peterの総報酬 ($USD 746.24K ) は、 US市場 ($USD 673.68K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Peterの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Peter Altman (57 yo)

22.5yrs

在職期間

US$746,237

報酬

Dr. Peter A. Altman, Ph.D. has been Chief Executive Officer and President of BioCardia, Inc. since 2002. Dr. Altman served as an acting Chief Executive Officer of Lumen Therapeutics from 2004 to 2005. He s...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Peter Altman	CEO, President & Director	22.5yrs	US$746.24k	2.15% $ 117.3k
David McClung	Chief Financial Officer	8.3yrs	US$469.47k	0.50% $ 27.1k
Edward Gillis	Senior Vice President of Devices	3.8yrs	US$326.37k	0.18% $ 9.7k

8.3yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: BCDAの経営陣は経験豊富で経験豊富です（平均在職期間は8.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Peter Altman	CEO, President & Director	22.5yrs	US$746.24k	2.15% $ 117.3k
Jay Moyes	Independent Director	13.5yrs	US$65.29k	0.20% $ 10.8k
Richard Krasno	Independent Director	7.8yrs	US$57.79k	0.17% $ 9.4k
William Facteau	Independent Director	less than a year	US$24.69k	データなし
Simon Stertzer	Independent Director	22.5yrs	US$47.55k	5.44% $ 297.0k
Jim Allen	Independent Director	4.8yrs	US$49.29k	3.27% $ 178.4k
Andrew Blank	Independent Chairman	4.8yrs	US$97.79k	1.84% $ 100.3k

7.8yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: BCDAの取締役会は経験豊富であると考えられます ( 7.7年の平均在任期間)。

BioCardia マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

BioCardia, Inc., Annual General Meeting, May 20, 2024

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

Recent updates

New major risk - Shareholder dilution

First quarter 2024 earnings released: US$0.09 loss per share (vs US$0.17 loss in 1Q 2023)

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc., Annual General Meeting, May 20, 2024

New major risk - Financial position

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioCardia, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

BioCardia Receives Determination Letter from the Staff that the Company Fails to Regain Compliance with the MVLS Requirement

BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

New major risk - Market cap size

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $2.75 million.

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million.

BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

New major risk - Negative shareholders equity

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Biocardia, Inc. Announces Completion of Enrollment in Phase Iii Cardiamp Hf Trial and Plans for Cardiamp Hf Trial Ii

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia, Inc. Announces Clarification and Next Steps on Its Autologous CardiAMP Cell Therapy Programs

Biocardia, Inc. Announces Interim Efficacy Results in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

Consensus revenue estimates decrease by 74%, EPS upgraded

New major risk - Revenue size

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

BioCardia, Inc. to Report First Half, 2023 Results on Aug 09, 2023

New major risk - Share price stability

Biocardia, Inc. Announces Dsmb Recommendation to Pause New Enrollment in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial While Additional Blinded Data Is Collected

BioCardia, Inc. Completes Submission of Cardiamp Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency

New minor risk - Share price stability

Insider recently bought US$177k worth of stock

Consensus revenue estimates increase by 86%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

BioCardia, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 24% to US$7.50

BioCardia, Inc. announced that it expects to receive $3.564989 million in funding

BioCardia, Inc. Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$9.88

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioCardia, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Insufficient new directors

Biocardia®, Inc. to Present New Data from Cardiamp Cell Therapy for Heart Failure Pivotal Trial At the Heart Failure Society of America Annual Meeting

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Consensus revenue estimates increase by 138%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioCardia, Inc. to Report First Half, 2022 Results on Aug 10, 2022

BioCardia, Inc. Announces US Patent on Imaging System for Targeting Cardiac Therapies

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 64%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation

BioCardia, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$10.63

Consensus forecasts updated

BioCardia, Inc. Announces FDA Approval of its IND for NK1R+ Mesenchymal Stem Cells

マネジメント基準チェック /44